Header Logo

Connection

Anthony Rothschild to Antidepressive Agents, Second-Generation

This is a "connection" page, showing publications Anthony Rothschild has written about Antidepressive Agents, Second-Generation.
  1. Moore BE, Rothschild AJ. Treatment of antidepressant-induced sexual dysfunction. Hosp Pract (1995). 1999 Jan 15; 34(1):89-91, 95-6.
    View in: PubMed
    Score: 0.153
  2. Ulbricht CM, Dumenci L, Rothschild AJ, Lapane KL. Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. Arch Womens Ment Health. 2016 10; 19(5):769-78.
    View in: PubMed
    Score: 0.124
  3. Ulbricht CM, Rothschild AJ, Lapane KL. Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. J Womens Health (Larchmt). 2016 05; 25(5):464-72.
    View in: PubMed
    Score: 0.122
  4. Ulbricht CM, Dumenci L, Rothschild AJ, Lapane KL. Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis. Am J Mens Health. 2018 Jan; 12(1):5-13.
    View in: PubMed
    Score: 0.122
  5. Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. J Nerv Ment Dis. 2013 Apr; 201(4):266-73.
    View in: PubMed
    Score: 0.102
  6. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.084
  7. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
    View in: PubMed
    Score: 0.070
  8. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
    View in: PubMed
    Score: 0.069
  9. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997 Apr 15; 41(8):837-43.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.